Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer

新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用

基本信息

  • 批准号:
    10301255
  • 负责人:
  • 金额:
    $ 26.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-05 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT DNA repair plays an important role in the pathogenesis of virtually all cancer types, and the identification of aberrant DNA repair pathways has identified predictive and prognostic biomarkers to targeted therapies. For example, epigenetic hypermethylation of the promoter of O6-methylguanine DNA methyltransferase (MGMT) predicts for better patient survival and increased sensitivity to temozolomide (TMZ) in multiple cancers, including colorectal cancer (CRC). TMZ is a monofunctional alkylator, and the DNA damage caused by TMZ is principally repaired by MGMT, which is silenced by promoter hypermethylation. The base excision repair (BER) pathway also serves as a critical pathway to repair TMZ DNA damage. Preclinically, the simultaneous inhibition of BER with polyp ADP ribose polymerase (PARP) inhibitors further sensitizes MGMT deficient tumors to TMZ. However, our preliminary findings reveal an alternative and parallel mechanism: TMZ damage causes acute replication stress and fork collapse leading to Ataxia Telangiectasia and Rad3 related (ATR) dependent phosphorylation of Checkpoint Kinase 1 (Chk1). We have leveraged these findings, and additional in vivo experiments, to advance novel TMZ combinations into the clinic with two investigator-initiated clinical trials for MGMT silenced CRC: 1) TMZ + olaparib (PARP inhibitor) and TMZ + AZD 6738 (ATR inhibitor). Enrollment will proceed at Yale Smilow Cancer Hospital with future opportunities expand to collaborating sites through our CRC Stand up to Cancer (SU2C) Dream Team. Furthermore, we aim to develop new biomarker assays including a biomarker assessing MGMT heterogeneity to identify tumors most sensitive to TMZ combinations, and perform genomic profiling. Leveraging DNA damage additionally represents a potential tool to stimulate an immune response, and through ancillary studies and using specimens obtained from our trials we will study the effects TMZ combinations on the immune microenvironment to lend support to the addition of immunotherapy in the future. I am a medical oncologist focusing on the treatment of advanced gastrointestinal (GI) cancers with an emphasis on innovative therapies for CRC. This award will facilitate my development as a physician- scientist equipped to design and conduct investigator-initiated early phase clinical trials based on innovative preclinical evidence regarding DNA repair and immunotherapies. My training will include didactic coursework for tumor immunology, practical experience of clinical trial implementation, and formal instruction in biomarker techniques. To achieve these goals, I have assembled a multidisciplinary mentorship team led by my primary mentor, Dr. Patricia LoRusso who has a proven track record of successfully mentoring junior faculty and extensive expertise in investigator-initiated clinical trials. At the conclusion of this award, I will have gained valuable skills into the underpinnings of clinical research generically, and specifically for clinical trial design, and biomarker identification for DNA repair and immunology. This award will help establish me as an independent investigator conducting early phase clinical trials for CRC and other GI cancers.
摘要 DNA修复在几乎所有癌症类型的发病机制中起着重要作用, 异常的DNA修复途径已经确定了靶向治疗的预测和预后生物标志物。为 例如,O 6-甲基鸟嘌呤DNA甲基转移酶(MGMT)启动子的表观遗传超甲基化 预测更好的患者生存率和增加敏感性替莫唑胺(TMZ)在多种癌症, 包括结肠直肠癌(CRC)。TMZ是一种单官能的烷基化剂,由TMZ引起的DNA损伤是 主要由MGMT修复,MGMT被启动子超甲基化沉默。碱基切除修复(BER) 这一途径也是修复TMZ DNA损伤的关键途径。临床前,同时抑制 BER与聚腺苷二磷酸核糖聚合酶(PARP)抑制剂的联合应用进一步使MGMT缺陷型肿瘤对TMZ敏感。 然而,我们的初步研究结果揭示了一种替代和平行的机制:TMZ损伤引起急性 复制应激和分叉塌陷导致共济失调毛细血管扩张和Rad 3相关(ATR)依赖 检查点激酶1(Chk 1)的磷酸化。我们利用这些发现,并在体内进行了额外的研究。 实验,推进新的TMZ组合进入临床,两个药物启动的临床试验, MGMT沉默CRC:1)TMZ +奥拉帕尼(PARP抑制剂)和TMZ + AZD 6738(ATR抑制剂)。招生将 继续在耶鲁Smilow癌症医院与未来的机会扩大到合作网站,通过我们的 CRC Stand Up to Cancer(SU 2C)梦之队此外,我们的目标是开发新的生物标志物检测方法, 包括评估MGMT异质性以鉴定对TMZ组合最敏感的肿瘤的生物标志物, 进行基因组分析利用DNA损伤还代表了一种潜在的工具,以刺激 免疫反应,并通过辅助研究和使用从我们的试验中获得的标本,我们将研究 TMZ组合对免疫微环境的影响,以支持添加免疫治疗 在未来我是一名医学肿瘤学家,专注于晚期胃肠道(GI)癌症的治疗 重点是CRC的创新疗法。这个奖项将促进我作为一名医生的发展- 科学家配备设计和进行制药商发起的早期临床试验的基础上,创新 关于DNA修复和免疫疗法的临床前证据。我的培训将包括教学课程 肿瘤免疫学,临床试验实施的实践经验,生物标志物的正式指导 技术.为了实现这些目标,我组建了一个多学科的导师团队, 导师,帕特里夏洛鲁索博士谁拥有成功指导初级教师和 在制药商发起的临床试验方面拥有广泛的专业知识。在这个奖项结束时,我将获得 有价值的技能到临床研究的基础一般,特别是临床试验设计, 以及用于DNA修复和免疫学的生物标志物鉴定。这个奖项将帮助我成为一个 进行CRC和其他GI癌症早期临床试验的独立研究者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Cecchini其他文献

Michael Cecchini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Cecchini', 18)}}的其他基金

Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
  • 批准号:
    10462786
  • 财政年份:
    2021
  • 资助金额:
    $ 26.1万
  • 项目类别:
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
  • 批准号:
    10675088
  • 财政年份:
    2021
  • 资助金额:
    $ 26.1万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 26.1万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了